COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02472561
Recruitment Status : Completed
First Posted : June 16, 2015
Last Update Posted : February 5, 2018
Verizon Wireless
Information provided by (Responsible Party):
Duke University

Brief Summary:

The purpose of this study is to understand the effects that a three month lifestyle-based mobile health (mHealth) peripheral artery disease (PAD) prevention program will have on improving physical activity, fitness, important PAD risk factors and quality of life (QOL) in patients with PAD.

By testing a novel mHealth intervention focused on lifestyle modification, this trial will address a critical evidence gap in the care of PAD patients. PAD patients are not eligible for cardiac rehabilitation and therefore struggle with unhealthy lifestyles, and these patients currently have no lifestyle-based care strategies to help them. The results of this study have the potential to lead to new sustainable and resource-efficient, lifestyle-based preventive care strategies for patients with stable PAD.

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Other: Fitbit Physical Activity Monitor Other: mHealth Glucometer Other: mHealth Blood Pressure Not Applicable

Detailed Description:

This is a single-center, randomized trial designed to examine the hypothesis that a lifestyle-based mHealth peripheral artery disease (PAD) prevention program will improve physical activity, fitness, important PAD risk factors and quality of life (QOL).

The investigators may enroll up to 55 men and women being evaluated for leg pain from Duke PAD cardiovascular clinics or after lower extremity angioplasty in the Duke catheterization laboratory. Of the 55 men and women volunteers who may be initially consented, the investigators anticipate a portion (potentially 20%) may drop out during the study timeline, and approximately 45 are expected to complete this study. Following informed consent and baseline testing, the participants will be randomized (1.25:1.00) into either a mHealth (N=25) or usual care group (N=20) [for comparison] for a 12-week period. All patients will be evaluated for walking ability on a treadmill test, quality of life questionnaires, health literacy related to PAD and the most important risk factors specific to PAD (blood glucose if diabetic, daily physical activity and blood pressure).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Verizon mHealth Solution for Elderly Underserved Patients With Peripheral Artery Disease
Study Start Date : July 2015
Actual Primary Completion Date : November 7, 2017
Actual Study Completion Date : November 7, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Mobile Health Application Group 1
Participants will wear a Fitbit Physical Activity Monitor to objectively quantify physical activity patterns. Once a week (± 3 days) during the 12 week mHealth intervention patients will measure and download their blood pressure and blood glucose (if diabetic) by means of a mHealth blood pressure cuff and mHealth glucometer. Medication adherence will be measured at baseline and 12-weeks by the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire. Each participant will be provided with a electronic version of the book titled, "Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease"; patients will be asked to read approximately one chapter per week for educational purposes.
Other: Fitbit Physical Activity Monitor
Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.

Other: mHealth Glucometer
Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
Other Name: Diabetics Only

Other: mHealth Blood Pressure
Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.

No Intervention: Usual Care Group 2
Participants will follow standard care as ordered by their individual, treating physician. Each participant will be given a paperback copy of the book, "Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease". All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments.

Primary Outcome Measures :
  1. Change in cardiovascular fitness level measured by change score analysis of peak Volume of Oxygen (pVO2mL/kg/min) consumption measured during a cardiopulmonary exercise test (CPET). [ Time Frame: Baseline and 12-week ]
    peak VO2 mL/kg/min

Secondary Outcome Measures :
  1. Feasibility of this novel mobile health treatment strategy, as measured by patient satisfaction survey [ Time Frame: 12-week ]
    Patient Satisfaction Survey

  2. Implementation of this novel mobile health treatment strategy, as measured by patient satisfaction [ Time Frame: 12-week ]
    Patient Satisfaction Survey

  3. Change in physical activity patterns (steps, time and distance) [ Time Frame: Baseline and 12-week ]
    Steps, time and distance per week

  4. Change score analysis in Body Mass Index measurements [ Time Frame: Baseline and 12-week ]
    Ratio of height to weight

  5. Change score analysis in Blood Glucose measurements [ Time Frame: Baseline and 12-week ]
    Fasting Plasma Glucose and Hemoglobin A1-C

  6. Change in Medication Adherence scores as measured by the Morisky Medication Adherence Scale (MMAS-8) [ Time Frame: Baseline and 12-week ]
  7. Change in Quality of Life (QOL) scores on the Walking Impairment Questionnaire [ Time Frame: Baseline and 12-week ]
  8. Change in Peripheral Artery Disease (PAD) Health Aptitude scores on the Health Aptitude Questionnaire [ Time Frame: Baseline and 12-week ]
  9. Change in Smoking Habits scores on the PAD: Smoking Habit Questionnaire [ Time Frame: Baseline and 12-week ]
  10. Change score analysis in Systolic and Diastolic Blood Pressure measurements [ Time Frame: Baseline and 12-week ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention
  • A history of stable intermittent claudication for >2 months, and an ABI <0.9 at rest
  • No contraindications to exercise training
  • All subjects will be on the recommended regimen of statin and antiplatelet therapy
  • Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study

Exclusion Criteria:

  • Present or a past history of gangrene, impending limb loss or osteomyelitis
  • Severe peripheral neuropathy
  • Any condition other than PAD that limits walking for example arthritis or chronic obstructive pulmonary disease (COPD)
  • Unstable angina, history of significant left main disease or three vessel coronary artery disease (>70% stenosis, unprotected by grafts) or recent myocardial infarction (less than eight weeks)
  • Chest pain during treadmill exercise which appears before the onset of claudication, or 2 mm ST depression during exercise regardless of the results of tests for myocardial ischemia
  • Refusal or inability to give informed consent or inability or unwillingness to comply with the study requirements.
  • Dementia that precludes ability to participate in and follow study protocols
  • Enrollment in a clinical trial not approved for co-enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02472561

Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Duke University
Verizon Wireless
Layout table for investigator information
Principal Investigator: Manesh R Patel, MD Duke University
Layout table for additonal information
Responsible Party: Duke University Identifier: NCT02472561    
Other Study ID Numbers: Pro00059885
First Posted: June 16, 2015    Key Record Dates
Last Update Posted: February 5, 2018
Last Verified: January 2018
Keywords provided by Duke University:
Peripheral Artery Disease
Mobile Health
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases